{
    "Trade/Device Name(s)": [
        "VITROS Immunodiagnostic Products CA 125 II Reagent Pack",
        "VITROS CA125 Reagent Pack"
    ],
    "Submitter Information": "Ortho-Clinical Diagnostics Inc.",
    "510(k) Number": "K221355",
    "Predicate Device Reference 510(k) Number(s)": [
        "K983875"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LTK"
    ],
    "Summary Letter Date": "April 27, 2022",
    "Summary Letter Received Date": "May 10, 2022",
    "Submission Date": "December 12, 2022",
    "Regulation Number(s)": [
        "21 CFR 866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 125 (OC 125 defined antigen)"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "VITROS 5600 Integrated System"
    ],
    "Method(s)/Technology(ies)": [
        "Immunometric immunoassay",
        "Chemiluminescent detection"
    ],
    "Methodologies": [
        "Immunoassay",
        "Luminescent detection"
    ],
    "Submission Type(s)": [
        "Reagent Pack",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for VITROS Immunodiagnostic Products CA 125 II Reagent Pack for quantitative measurement of OC 125 antigen using immunometric immunoassay on VITROS 5600 system",
    "Indications for Use Summary": "Quantitative measurement of OC 125 antigen in human serum and plasma using the VITROS 5600 system to aid in monitoring response to therapy in patients with epithelial ovarian cancer; serial CA 125 testing should be used with other clinical methods.",
    "fda_folder": "Immunology"
}